In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors

Amano, 1996, Neuropharmacological effects of sigma ligands, Jpn. J. Psychopharmacol., 16, 73

Bem, 1991, Overexpression of σ receptors in nonneural human tumors, Cancer Res, 51, 6558

Bouchard, 1996, Autoradiographic evidence for the modulation of in vivo sigma receptor labeling by neuropeptide Y and calcitonin gene-related peptide in the mouse brain, J. Pharmacol. Exp. Ther., 276, 223

Bowen, 1989, Evidence for a multisite model of the rat brain σ receptor, Eur. J. Pharmacol., 163, 309, 10.1016/0014-2999(89)90200-8

Collier, 1996, Synthesis of [18F]-1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine, J. Labelled Compd. Radiopharm., 38, 786

Contreras, 1987, Autoradiographic distribution of non-dopaminergic binding sites labeled by [3H]haloperidol in rat brain, Neurosci. Lett., 75, 133, 10.1016/0304-3940(87)90286-2

Danso-Danquah, 1995, Synthesis and σ binding properties of 2′-substituted 5,9α-dimethyl-6,7-benzomorphans, J. Med. Chem., 38, 2978, 10.1021/jm00015a022

Dence, 1997, Synthesis and evaluation of [18F] labeled benzamides, Nucl. Med. Biol., 24, 333, 10.1016/S0969-8051(97)00001-2

Ding, 1993, Synthesis and PET studies of fluorine-18-BMY14802, J. Nucl. Med., 34, 246

Fujimura, 1997, Synthesis, structure and quantitative structure-activity relationships of σ receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines, Bioorg. Med. Chem., 5, 1675, 10.1016/S0968-0896(97)00093-X

Hellewell, 1994, Rat liver and kidney contain high densities of σ1 and σ2 receptors, Eur. J. Pharmacol., 268, 9, 10.1016/0922-4106(94)90115-5

Ishiwata, 1998, Synthesis of [11C]NE-100 labeled in two different positions as a PET σ receptor ligand, Nucl. Med. Biol., 25, 195, 10.1016/S0969-8051(97)00170-4

Ishiwata, 1999, Comparison of three PET dopamine D2-like receptor ligands, [11C]raclopride, [11C]nemonapride and [11C]N-methylspiperone, in rats, Ann. Nucl. Med., 13, 161, 10.1007/BF03164856

John, 1993, A malignant melanoma imaging agent, J. Nucl. Med., 34, 2169

John, 1994, Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new receptor radiopharmaceutical, J. Med. Chem., 37, 1737, 10.1021/jm00038a002

John, 1995, Synthesis and pharmacological characterization of 4-[125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, Cancer Res, 55, 3022

John, 1996, Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl)ethylamine, Nucl. Med. Biol., 23, 761, 10.1016/0969-8051(96)00070-4

Kawamura, 1999, Synthesis and in vivo evaluation of [11C]SA6298 as a PET sigma1 receptor ligand, Nucl. Med. Biol., 26, 915, 10.1016/S0969-8051(99)00069-4

Kiesewater, 1993, Synthesis of N1-3-[18F]-fluoropropyl-N4-2-([3,4-dichlorophenyl]ethyl)piperadine, a high affinity ligand for sigma receptor, J. Labelled Compd. Radiopharm., 33, 639, 10.1002/jlcr.2580330711

Matsuno, 1996, σ1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test, Eur. J. Pharmacol., 312, 267, 10.1016/0014-2999(96)00497-9

Matsuno, 1998, SA4503, CNS Drug Rev, 4, 1, 10.1111/j.1527-3458.1998.tb00038.x

Matsuno, 1996, Binding properties of SA4503 a novel and selective σ1 receptor agonist, Eur. J. Pharmacol., 306, 271, 10.1016/0014-2999(96)00201-4

Matsuno, 1997, SA4503, a novel cognitive enhancer, with σ1 receptor agonistic properties, Behav. Brain Res., 83, 221, 10.1016/S0166-4328(97)86074-3

Matsuno, 1993, Correlation between potentiation of neurogenic twitch contraction and benzomorphan σ receptor binding potency in the mouse vas deferens, Eur. J. Phamacol., 231, 451, 10.1016/0014-2999(93)90123-Y

Maurice, 1997, Neuroprotective and anti-amnesic potentials of sigma (σ) ligands, Prog. Neuro-Psychoph., 21, 69, 10.1016/S0278-5846(96)00160-1

Michelot, 1991, Synthesis and evaluation of new iodide-125 radiopharmaceuticals as potential tracers for malignant melanoma, J. Nucl. Med., 31, 1573

Musachio, 1994, (+)-[C-11]cis-N-benzyl-normetazocine, Life Sci, 55, L225, 10.1016/0024-3205(94)90051-5

Nabeshima, 1994, Physiological function of sigma receptors, Jpn. J. Psychopharmacol., 14, 51

Quirion, 1992, A proposal for the classification of σ binding sites, Trends Pharmacol. Sci., 13, 85, 10.1016/0165-6147(92)90030-A

Sircar, 1986, Characterization and autoradiographic visualization of (+)-[3H]SKF10,047 binding in rat and mouse brain, J. Pharmacol. Exp. Ther., 237, 681

Seth, 1998, Cloning and functional characterization of a σ receptor from rat brain, J. Neurochem., 70, 922, 10.1046/j.1471-4159.1998.70030922.x

Shiue, 1993, Synthesis (±)-[18F]-BMY14802, its enantiomers and their anatomical distributions in rodents, Nucl. Med. Biol., 20, 625, 10.1016/0969-8051(93)90031-O

Shiue, 1997, N-(N-benzylpiperidin-4-yl)-2-[18F]fluorobenzamide, Nucl. Med. Biol., 24, 671, 10.1016/S0969-8051(97)00097-8

Su, 1988, Steroid binding at σ receptors suggests a link between endocrine, nervous, immune systems, Science, 240, 219, 10.1126/science.2832949

Vilner, 1995, Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines, Cancer Res, 55, 408

Walker, 1990, Sigma receptors, Pharmacol. Rev., 42, 355

Waterhouse, 1996, Synthesis of a selective sigma receptor radioligand for SPECT, J. Labelled Compd. Radiopharm., 38, 595, 10.1002/(SICI)1099-1344(199607)38:7<595::AID-JLCR882>3.0.CO;2-A

Waterhouse, 1997, In vivo evaluation of [18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine, Nucl. Med. Biol., 24, 127, 10.1016/S0969-8051(96)00184-9

Weissman, 1990, In vivo binding of [3H]d-N-allylnormetazosine and [3H]haloperidol to sigma receptors in the mouse brain, J. Chem. Neuroanat., 3, 347

Wolfe, 1989, σ-Receptors in endocrine organs, Endocrinology, 124, 1160, 10.1210/endo-124-3-1160